Pfizer Revenue and Competitors
Estimated Revenue & Valuation
- Pfizer's estimated annual revenue is currently $69.3B per year.
- Pfizer's estimated revenue per employee is $714,396
- Pfizer's current valuation is $308.4B. (January 2022)
Employee Data
- Pfizer has 97061 Employees.
- Pfizer grew their employee count by 7% last year.
Pfizer Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $11830M | 4867 | 30% | $2.7B | $83B |
#2 | $32820M | 94442 | 6% | N/A | $182.4B |
#3 | $15.9M | 79 | 7% | N/A | N/A |
What Is Pfizer?
Pfizer Inc discovers, develops, manufactures, and markets leading prescription medicines for humans and animals and many of the world's best-known consumer brands. Our innovative, value-added products improve the quality of life of people around the world and help them enjoy longer, healthier, and more productive lives. The company has three business segments: health care, animal health and consumer health care. Our products are available in more than 150 countries.
keywords:BiotechnologyN/A
Total Funding
97061
Number of Employees
$69.3B
Revenue (est)
7%
Employee Growth %
$308.4B
Valuation
N/A
Accelerator
Pfizer News
Reports of two patients who found relief from long COVID after taking Pfizer Inc's antiviral Paxlovid, including a researcher who tested it...
Worldwide demand for Pfizer Inc's oral COVID-19 antiviral treatment Paxlovid has been unexpectedly light due to complicated eligibility...
Reports of two patients who found relief from long COVID after taking Pfizer Inc's antiviral Paxlovid, including a researcher who tested it...
Pfizer Announces Topline Results from Phase 2b Trial of Vupanorsen in Statin-treated Participants with Dyslipidemia Study met its primary endpoint, achieving a statistically significant reduction in non-high density lipoprotein cholesterol (non-HDL-C) - as well as a statistically significant r ...
NEW HAVEN, Conn. and NEW YORK, Nov. 9, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) and Pfizer Inc. (NYSE: PFE), today announced a strategic commercialization arrangement for rimegepant in markets outside of the United States upon approval. Rimegepant is commerc ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $30740M | 97270 | 4% | N/A |
#2 | $24790M | 98424 | -3% | N/A |
#3 | $34920M | 116894 | 1% | N/A |
#4 | $19100M | 120560 | 13% | N/A |
#5 | $19100M | 132710 | 9% | N/A |